These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37439076)

  • 1. The importance of the "how": the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment.
    Grimsrud A; Wilkinson L; Delany-Moretlwe S; Ehrenkranz P; Green K; Murenga M; Ngure K; Otwoma NJ; Phanuphak N; Vandevelde W; Vitoria M; Bygrave H
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26095. PubMed ID: 37439076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancing the use of Long-Acting Extended Delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations.
    Mgodi NM; Murewanhema G; Moyo E; Samba C; Musuka G; Dzinamarira T; Brown JM
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26115. PubMed ID: 37439069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparing for long-acting PrEP delivery: building on lessons from oral PrEP.
    Celum C; Grinsztejn B; Ngure K
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26103. PubMed ID: 37439077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stand-alone model for delivery of oral HIV pre-exposure prophylaxis in Kenya: a single-arm, prospective pilot evaluation.
    Ortblad KF; Mogere P; Omollo V; Kuo AP; Asewe M; Gakuo S; Roche S; Mugambi M; Mugambi ML; Stergachis A; Odoyo J; Bukusi EA; Ngure K; Baeten JM
    J Int AIDS Soc; 2023 Jun; 26(6):e26131. PubMed ID: 37306128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interrogating the promise of long-acting HIV pre-exposure prophylaxis.
    Pike C; Bekker LG
    Trends Mol Med; 2023 Feb; 29(2):93-98. PubMed ID: 36435632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What does the scale-up of long-acting HIV pre-exposure prophylaxis mean for the global hepatitis B epidemic?
    Mohareb AM; Kouamé MG; Nouaman M; Kim AY; Larmarange J; Neilan AM; Lacombe K; Freedberg KA; Boyd A; Coffie P; Hyle EP
    J Int AIDS Soc; 2024 Mar; 27(3):e26218. PubMed ID: 38444112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV prevention: better choice for better coverage.
    Bekker LG; Pike C; Hillier SL
    J Int AIDS Soc; 2022 Jan; 25(1):e25872. PubMed ID: 35030296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-exposure prophylaxis (PrEP) for HIV prevention among people who inject drugs: a global mapping of service delivery.
    Shaw G; Schaefer R; Schmidt HA; Madden A; Chang J; Mozalevskis A; Msimanga-Radebe B; Mangadan Konath N; Verster A; Baggaley R; Rodolph M; Macdonald V
    Harm Reduct J; 2023 Feb; 20(1):16. PubMed ID: 36782321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "It went through the roof": an observation study exploring the rise in PrEP uptake among Zimbabwean female sex workers in response to adaptations during Covid-19.
    Matambanadzo P; Busza J; Mafaune H; Chinyanganya L; Machingura F; Ncube G; Steen R; Phillips A; Cowan FM
    J Int AIDS Soc; 2021 Oct; 24 Suppl 6(Suppl 6):e25813. PubMed ID: 34713613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy.
    Cáceres CF; Borquez A; Klausner JD; Baggaley R; Beyrer C
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21108. PubMed ID: 27760685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Online HIV prophylaxis delivery: Protocol for the ePrEP Kenya pilot study.
    Kiptinness C; Naik P; Thuo N; Malen RC; Dettinger JC; Pintye J; Rafferty M; Jomo E; Nyamasyo N; Wood T; Isabelli P; Morris S; Hattery D; Stergachis A; Were D; Sharma M; Ngure K; Mugambi ML; Ortblad KF
    Front Public Health; 2023; 11():1054559. PubMed ID: 36908449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery.
    Henderson M; Schmidt HA; Chitembo L; Peralta H; Alaama AS; Johnson C; Baggaley R; Schaefer R
    AIDS Behav; 2023 Nov; 27(11):3755-3766. PubMed ID: 37351685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders.
    Mack N; Odhiambo J; Wong CM; Agot K
    BMC Health Serv Res; 2014 May; 14():231. PubMed ID: 24886646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commentary: the value of PrEP for people who inject drugs.
    Coleman RL; McLean S
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21112. PubMed ID: 27760686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.
    Hodges-Mameletzis I; Fonner VA; Dalal S; Mugo N; Msimanga-Radebe B; Baggaley R
    Drugs; 2019 Aug; 79(12):1263-1276. PubMed ID: 31309457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current landscape of pre-exposure prophylaxis service delivery models for HIV prevention: a scoping review.
    Vanhamel J; Rotsaert A; Reyniers T; Nöstlinger C; Laga M; Van Landeghem E; Vuylsteke B
    BMC Health Serv Res; 2020 Jul; 20(1):704. PubMed ID: 32736626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public Health Implications of Adapting HIV Pre-exposure Prophylaxis Programs for Virtual Service Delivery in the Context of the COVID-19 Pandemic: Systematic Review.
    Patel P; Kerzner M; Reed JB; Sullivan PS; El-Sadr WM
    JMIR Public Health Surveill; 2022 Jun; 8(6):e37479. PubMed ID: 35486813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What will it take for an injectable ARV to change the face of the HIV epidemic in high-prevalence countries? Considerations regarding drug costs and operations.
    Meyer-Rath G; Jamieson L; Pillay Y
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26106. PubMed ID: 37439062
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.